IRIS
PATRIARCA, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.136
AS - Asia 6.153
EU - Europa 4.015
SA - Sud America 1.328
Continente sconosciuto - Info sul continente non disponibili 707
AF - Africa 131
OC - Oceania 6
Totale 27.476
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.851
SG - Singapore 2.818
CN - Cina 1.337
UA - Ucraina 1.068
BR - Brasile 1.059
HK - Hong Kong 636
IT - Italia 598
DE - Germania 575
VN - Vietnam 486
FI - Finlandia 410
RU - Federazione Russa 305
FR - Francia 254
SE - Svezia 242
IE - Irlanda 207
BD - Bangladesh 196
CA - Canada 161
IN - India 139
GB - Regno Unito 129
TR - Turchia 113
AR - Argentina 92
KR - Corea 74
IQ - Iraq 63
CO - Colombia 50
MX - Messico 48
EC - Ecuador 39
NL - Olanda 39
ID - Indonesia 32
AT - Austria 31
JP - Giappone 30
ZA - Sudafrica 30
PL - Polonia 29
PK - Pakistan 28
VE - Venezuela 24
IR - Iran 21
BE - Belgio 20
UZ - Uzbekistan 20
CL - Cile 19
MA - Marocco 19
PY - Paraguay 19
PH - Filippine 18
SA - Arabia Saudita 17
ES - Italia 16
CZ - Repubblica Ceca 14
EU - Europa 14
KE - Kenya 14
TN - Tunisia 14
AE - Emirati Arabi Uniti 13
MY - Malesia 13
PE - Perù 13
JM - Giamaica 12
RO - Romania 12
CR - Costa Rica 10
RS - Serbia 10
AZ - Azerbaigian 9
CH - Svizzera 9
EG - Egitto 9
KZ - Kazakistan 9
NP - Nepal 9
GT - Guatemala 8
IL - Israele 8
JO - Giordania 8
TG - Togo 8
TT - Trinidad e Tobago 8
OM - Oman 7
PA - Panama 7
AL - Albania 6
AU - Australia 6
BO - Bolivia 6
DZ - Algeria 6
GE - Georgia 6
HN - Honduras 6
KG - Kirghizistan 6
NI - Nicaragua 6
PT - Portogallo 6
DO - Repubblica Dominicana 5
GA - Gabon 5
LT - Lituania 5
PS - Palestinian Territory 5
UY - Uruguay 5
BB - Barbados 4
BG - Bulgaria 4
BH - Bahrain 4
LB - Libano 4
TH - Thailandia 4
TW - Taiwan 4
BA - Bosnia-Erzegovina 3
BY - Bielorussia 3
CM - Camerun 3
ET - Etiopia 3
LV - Lettonia 3
MD - Moldavia 3
QA - Qatar 3
SN - Senegal 3
AM - Armenia 2
AO - Angola 2
CI - Costa d'Avorio 2
DK - Danimarca 2
GY - Guiana 2
KH - Cambogia 2
LR - Liberia 2
Totale 26.741
Salva come PNG Salva come JPEG
Città #
Fairfield 1.589
Woodbridge 1.364
Ashburn 1.184
Singapore 1.136
Houston 1.012
Ann Arbor 893
Jacksonville 704
Wilmington 644
Seattle 638
Hong Kong 632
Beijing 621
Chandler 569
San Jose 562
Council Bluffs 517
Cambridge 511
Dearborn 454
Boardman 296
Dallas 242
Lauterbourg 216
Princeton 211
Dublin 204
Los Angeles 179
Ho Chi Minh City 154
Udine 150
San Diego 101
Buffalo 99
São Paulo 99
Hanoi 95
Santa Clara 93
Hefei 89
New York 89
Redondo Beach 79
Izmir 78
Dong Ket 69
Seoul 68
Munich 66
Helsinki 57
Ogden 52
Des Moines 46
Norwalk 43
Ottawa 43
Nuremberg 41
Frankfurt am Main 39
The Dalles 38
Chicago 37
Montreal 33
Rio de Janeiro 33
Rome 33
Milan 31
Pittsburgh 29
Toronto 29
Kunming 28
Trieste 28
Atlanta 27
Turku 27
Nanjing 26
Baghdad 25
Phoenix 25
Belo Horizonte 24
Denver 24
Mumbai 24
Warsaw 24
Dhaka 23
Tokyo 23
Brasília 22
Bogotá 21
Curitiba 21
Lappeenranta 21
Guangzhou 19
Haiphong 19
Orem 19
Redmond 19
Brussels 18
Da Nang 18
Shanghai 18
Brooklyn 17
Chennai 17
Tashkent 17
Poplar 16
San Francisco 16
Stockholm 16
Boston 15
Hyderabad 15
Nanchang 15
Salvador 15
Guayaquil 14
Amsterdam 13
London 13
Naples 13
Porto Alegre 13
Shenzhen 13
Simi Valley 13
Campinas 12
Düsseldorf 12
Las Vegas 12
Manchester 12
Quito 12
Vienna 12
Ankara 11
Duino-Aurisina 11
Totale 17.179
Salva come PNG Salva come JPEG
Nome #
Long-Term Outcome of Fanconi Anemia Patients From the Italian Registry on Behalf of the Marrow Failure Study Group of the AIEOP (Italian Association for Pediatric Haematology-Oncology) 391
Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy 282
Combined orthotopic heart transplantation followed by autologous stem cell transplantation in a patient with light chain amyloidosis and isolated cardiac involvement 227
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 222
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 216
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)” 204
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 201
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 196
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 193
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 191
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). 190
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 186
A comparison of allografting with autografting for newly diagnosed myeloma 185
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability 184
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation 183
JAK-2 inhibitors and allogeneic transplant in myelofibrosis 177
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 176
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 174
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 173
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. 172
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 171
Clinical feature and outcome in seven patients wuth hyaline or mixed variant of Castleman’s disease. A single centre experience 169
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 169
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 167
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 166
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation 165
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 163
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. 163
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 162
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation 158
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 156
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) 156
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group 155
Allogeneic stem cell transplantation and novel therapies: is the treatment paradigm for younger patients with chronic lymphocytic leukemia changing? 153
Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon. 152
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease 152
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib 152
Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma 151
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. 150
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. 150
Acute myeloid leukemia following chronic low-dose cyclophosphamide in metastatic breast cancer 148
Rituximab for the treatment of type II mixed cryoglobulinemia 148
‘Real-life’ report on the management of chronic GvHD in the gruppo Italiano trapianto midollo osseo (GITMO) 147
Defibrotide : review on clinical use and future development 146
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 146
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 146
Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors. 145
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 144
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. 144
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 144
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 143
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. 141
Multiple Myeloma: presenting features and survival according to hospital referral 140
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. 139
Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant patients: intercontinental prospective study of Infectious Diseases Working Party of the European Bone Marrow Transplantation group 139
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous transplantation 138
Flow cytometry evaluation of plasma cells contaminating leukapheresis pre- and post- CD34-positive selection- 138
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 138
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study 138
A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of aurtologoaus stem cell transplantation in first remission on autcome 135
CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide 135
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) 134
Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin’s lymphomas 133
Sequential study of cytokine and lymphocyte patterns in patients with chronic agraft versus host disease after reduced intensity conditioning allogenic stem cell transplantation 133
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 133
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey in 50 patients 133
Albumina: ricaduta delle linee guida aziendali sui consumi 132
Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy. 132
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients 130
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 130
Impact of Cryopreservation of Peripheral Blood Stem Cells (PBSC) in Transplantation from Matched Unrelated Donor (MUD) 129
High dose therapy with stem cell rescue in elderly atients with aggressive poor risk lymphomas: a review of 14 cases. 129
A prospective comparison of 18 F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disaese in newly diagnosed multiple myeloma 129
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. 129
Qualitative and quantitative polymerase chain reaction monitoring minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation . 129
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation 128
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. 128
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis 128
Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous: a retrospective study based on the time of HLA typing and donor availability 126
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. 126
Long lasting remission after haploidentical stem cell transplant and pre-emptive donor lymphocyte infusions in a patient with primary refractory Hodgkin lymphoma 124
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. 124
Treatment of refractory chronic GVHD with rituximab: a GITMO study 123
FEASIBILITY AND OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 60 YEARS WITH POOR RISK ACUTE MYELOID LEUKEMIA 122
Successful treatment of hematological and extramedullary relapse of MLL-positive acute lymphoblastic leukemia after bone marrow transplantation using donor leukocyte infusion 122
Experts' considerations on HLA-haploidentical stem cell transplantation. 122
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group 121
Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy 121
Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant 121
Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) 121
Cytokines dysregulation and chronic graft versus host disease after allogeneic haematopoieitc stem cell transplantation with reduced intensity conditioning 120
Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation. 120
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation 120
Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. 120
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. 120
Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. 118
Non-myeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo 118
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation 118
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. 117
Autologous transplantation and maintenance therapy in multiple myeloma 117
Totale 15.165
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.418
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.418
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.338 0 0 85 102 37 69 101 77 15 269 328 255
2022/20231.465 224 73 13 177 142 428 1 103 220 17 32 35
2023/2024489 64 28 10 17 67 53 25 43 81 46 26 29
2024/20253.788 86 285 121 89 295 190 184 240 351 368 551 1.028
2025/20267.667 547 783 681 791 988 621 886 275 488 735 527 345
2026/20271.200 248 599 353 0 0 0 0 0 0 0 0 0
Totale 27.476